BRANFORD — On September 27 Gov. Dannel P. Malloy announced that the state would provide up to $2.25 million in grants to Durata Therapeutics Inc. to support the relocation of its research and development, clinical and regulatory operations from Morristown, N.J. to Branford. " turn the bioscience firm, whose headquarters are in Chicago, has pledged to create up to 80 new, full-time jobs in Connecticut.
Durata will be leasing some 18,000 square feet of space in Branford for research, clinical and regulatory work.
The move is the latest in a series of initiatives that have been announced since Malloy launched his Bioscience Connecticut plan last year. The objective of Bioscience Connecticut is to position the state for sustained economic growth driven by research, development, and commercialization of new technologies and products.
“The goal of Bioscience Connecticut is twofold: creating good paying jobs with good benefits for residents in an industry that is poised for growth,” explained Malloy. “With the addition of Durata Therapeutics, we are further cementing the state as a destination for health and life science companies. Connecticut will continue to cultivate new investment, attract new talent, and work with our entrepreneurs to develop our workforce and strengthen our state’s position as a global leader in this rapidly expanding field.”
“We are thrilled to welcome Durata Therapeutics to Branford and are grateful to the Governor for helping the company choose Connecticut,” said Branford State Rep. Lonnie Reed " /#valium_generic">valium generic. “Durata promises to create at least 80 substantial jobs, has huge potential for growth and joins a community of Branford life sciences firms dedicated to curing diseases and saving lives.”
A clinical development-stage biopharmaceutical firm founded in 2009, Durata is focused on the growing need for new therapeutics to treat infectious diseases. It acquired the rights to a pharmaceutical drug and two other products through acquisition of Vicuron Pharmaceuticals from Pfizer and is currently in the late stages of development of dalbavancin for acute bacterial skin and skin structure infections (otherwise known as abSSSI), including MRSA.
Total capital investment in Connecticut over the next ten years is estimated to be $13 million. This includes $2 million of state assistance provided by the Department of Economic & Community Development (DECD), which will be used for leasehold improvements; research and development; furniture, fixtures and equipment; relocation costs; and other project-related expenses, and will be disbursed based on job creation milestones. The remaining $250,000 will be provided as a training grant.
|< Prev||Next >|